Search

Displaying results 4911 - 4920 of 10000 in total
  1. Drug

    Mericitabine

    go.drugbank.com/drugs/DB12045
    Investigational

    PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication. … Mericitabine is a prodrug of PSI-6130, which demonstrated excellent potency in preclinical studies.

  2. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching. … As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application.

    Mixtures: LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO, LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO
  3. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

  4. Drug

    Cefodizime

    go.drugbank.com/drugs/DB13470
    Investigational

    Cefodizime is a third generation cephalosporin with a broad spectrum of antibacterial activity.[A275053, A275058]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Isothipendyl

    go.drugbank.com/drugs/DB08802
    Investigational

    Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical Use
  6. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is a small molecule drug. Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients). … Maytansine has a monoisotopic molecular weight of 691.29 Da.

  7. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Golotimod

    go.drugbank.com/drugs/DB05475
    Investigational

    SCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway. … Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis. It can be administered orally or subcutaneously.

  9. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    It is developed for the treatment of obesity and other metabolic disorders. … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  10. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. … HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.